Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 10, 2021

SELL
$85.37 - $114.1 $1.23 Million - $1.65 Million
-14,445 Closed
0 $0
Q1 2021

May 14, 2021

BUY
$109.73 - $153.66 $1.59 Million - $2.22 Million
14,445 New
14,445 $1.66 Million

Others Institutions Holding ALLK

About Allakos Inc.


  • Ticker ALLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 84,726,096
  • Market Cap $89.8M
  • Description
  • Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...
More about ALLK
Track This Portfolio

Track Cornerstone Partners Capital Management, LLC Portfolio

Follow Cornerstone Partners Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cornerstone Partners Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cornerstone Partners Capital Management, LLC with notifications on news.